scispace - formally typeset
P

Pingxin Li

Researcher at Pennsylvania State University

Publications -  8
Citations -  2869

Pingxin Li is an academic researcher from Pennsylvania State University. The author has contributed to research in topics: Histone & Histone citrullination. The author has an hindex of 7, co-authored 8 publications receiving 2425 citations. Previous affiliations of Pingxin Li include Foundation University, Islamabad.

Papers
More filters
Journal ArticleDOI

Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation

TL;DR: It is shown that the hypercitrullination of histones by PAD4 mediates chromatin decondensation in granulocytes/neutrophils, and citrullinations of biochemically defined avian nucleosome arrays inhibits their compaction by the linker histone H5 to form higher order chromatin structures.
Journal ArticleDOI

PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps

TL;DR: It is found that citrullination decreased the bacterial killing activity of histones and nucleosomes, which suggests that PAD4 mainly plays a role in chromatin decondensation to form NETs instead of increasing histone-mediated bacterial killing.
Journal ArticleDOI

Regulation of p53 Target Gene Expression by Peptidylarginine Deiminase 4

TL;DR: It is reported that peptidylarginine deiminase 4, a histone citrullination enzyme, is involved in the repression of p53 target genes.
Journal ArticleDOI

Histone Arg Modifications and p53 Regulate the Expression of OKL38, a Mediator of Apoptosis

TL;DR: OKL38 is identified as a novel p53 target gene that is regulated by PAD4 and plays a role in apoptosis, and it is found that OKL38 induces apoptosis through localization to mitochondria and induction of cytochrome c release.
Journal ArticleDOI

Anticancer Peptidylarginine Deiminase (PAD) Inhibitors Regulate the Autophagy Flux and the Mammalian Target of Rapamycin Complex 1 Activity

TL;DR: PAD4 regulates the mTORC1 signaling pathway and that PAD inhibitors are potential anticancer reagents that activate tumor suppressor gene expression alone or in combination with histone deacetylase inhibitors.